Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes

Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Epiretinal Membrane Age Related Macular Degeneration Choroid Diseases Choroidal Neovascularization Eye Diseases Macular Degeneration Metaplasia Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms Retinal Degeneration Retinal Diseases Uveal Diseases

Age range

58 year–90 year

Sex eligibility

All sexes

Study type

Observational

About this study

Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular degeneration. Since then we have seen that is not rare to find the coexistence of these entities. An ERM may produce intrinsic disorganization of the outer retina leading to persistent increased macular thickness and/or edema. This persistent edema may affect the effectiveness in the treatment of exudative age-related macular degeneration (eAMD). Therefore, this study was designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Significant epiretinal membrane
Anti-VEGF treatment for age-related macular degeneration

Exclusion criteria

Uveitis
Macular disorders
Diabetic retinopathy
Vascular occlusions

Treatment and study plan

Primary outcomes

Best corrected visual acuity

Time frame: 12 months

Evaluate the best visual acuity during the follow up.
Central macular thickness

Time frame: 12 months

Evaluation of the retinal thickness changes with anti-VEGF treatment
Fluorescein angiogram

Time frame: 12 months

Evaluation of changes in lesion size during follow-up.

Sponsors and collaborators

Lead sponsor

New England Retina Associates

Other

Registry information

Official study title

Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-related Macular Degeneration With Concurrent Significant Epiretinal Membrane.

Important dates

Study start: 2006
Primary completion: 2010
Study completion: 2010
First posted: May 3, 2013
Registry last updated: May 3, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed